Literature DB >> 25678989

Dried-leaf Artemisia annua: A practical malaria therapeutic for developing countries?

Pamela J Weathers1, Melissa Towler1, Ahmed Hassanali2, Pierre Lutgen3, Patrick Ogwang Engeu4.   

Abstract

Artemisinin from the plant Artemisia annua (A. annua) L, and used as artemisinin combination therapy (ACT), is the current best therapeutic for treating malaria, a disease that hits children and adults especially in developing countries. Traditionally, A. annua was used by the Chinese as a tea to treat "fever". More recently, investigators have shown that tea infusions and oral consumption of the dried leaves of the plant have prophylactic and therapeutic efficacy. The presence of a complex matrix of chemicals within the leaves seems to enhance both the bioavailability and efficacy of artemisinin. Although about 1000-fold less potent than artemisinin in their antiplasmodial activity, these plant chemicals are mainly small molecules that include other artemisinic compounds, terpenes (mainly mono and sesqui), flavonoids, and polyphenolic acids. In addition, polysaccharide constituents of A. annua may enhance bioavailability of artemisinin. Rodent pharmacokinetics showed longer T1/2 and Tmax and greater Cmax and AUC in Plasmodium chabaudi-infected mice treated with A. annua dried leaves than in healthy mice. Pharmacokinetics of deoxyartemisinin, a liver metabolite of artemisinin, was more inhibited in infected than in healthy mice. In healthy mice, artemisinin serum levels were > 40-fold greater in dried leaf fed mice than those fed with pure artemisinin. Human trial data showed that when delivered as dried leaves, 40-fold less artemisinin was required to obtain a therapeutic response compared to pure artemisinin. ACTs are still unaffordable for many malaria patients, and cost estimates for A. annua dried leaf tablet production are orders of magnitude less than for ACT, despite improvements in the production capacity. Considering that for > 2000 years this plant was used in traditional Chinese medicine for treatment of fever with no apparent appearance of artemisinin drug resistance, the evidence argues for inclusion of affordable A. annua dried leaf tablets into the arsenal of drugs to combat malaria and other artemisinin-susceptible diseases.

Entities:  

Keywords:  Artemisia annua; Artemisinin; Artemisinin combination therapy; Combination therapy; Infectious disease; Malaria

Year:  2014        PMID: 25678989      PMCID: PMC4323188          DOI: 10.5497/wjp.v3.i4.39

Source DB:  PubMed          Journal:  World J Pharmacol        ISSN: 2220-3192


  97 in total

1.  Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin.

Authors:  Thomas Efferth; Florian Herrmann; Ahmed Tahrani; Michael Wink
Journal:  Phytomedicine       Date:  2011-08-09       Impact factor: 5.340

2.  Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults.

Authors:  M Ashton; T N Hai; N D Sy; D X Huong; N Van Huong; N T Niêu; L D Công
Journal:  Drug Metab Dispos       Date:  1998-01       Impact factor: 3.922

3.  Saccharide anions as inhibitors of the malaria parasite.

Authors:  D L Clark; S Su; E A Davidson
Journal:  Glycoconj J       Date:  1997-06       Impact factor: 2.916

Review 4.  Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites.

Authors:  J Utzinger; S Xiao; J Keiser; M Chen; J Zheng; M Tanner
Journal:  Curr Med Chem       Date:  2001-12       Impact factor: 4.530

Review 5.  Comparative assessment of technologies for extraction of artemisinin.

Authors:  Alexei A Lapkin; Pawel K Plucinski; Malcolm Cutler
Journal:  J Nat Prod       Date:  2006-11       Impact factor: 4.050

Review 6.  Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria.

Authors:  P J de Vries; T K Dien
Journal:  Drugs       Date:  1996-12       Impact factor: 9.546

7.  Herba Artemisiae annuae tea preparation compared to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in adults: a randomized double-blind clinical trial.

Authors:  Christoph H Blanke; Godson B Naisabha; Mussa B Balema; Godfrey M Mbaruku; Lutz Heide; Markus S Müller
Journal:  Trop Doct       Date:  2008-04       Impact factor: 0.731

8.  [Pharmacokinetics of dihydroqinghaosu in human volunteers and comparison with qinghaosu].

Authors:  K C Zhao; Z Y Song
Journal:  Yao Xue Xue Bao       Date:  1993

9.  Cost of increasing access to artemisinin combination therapy: the Cambodian experience.

Authors:  Shunmay Yeung; Wim Van Damme; Duong Socheat; Nicholas J White; Anne Mills
Journal:  Malar J       Date:  2008-05-20       Impact factor: 2.979

10.  Common dietary flavonoids inhibit the growth of the intraerythrocytic malaria parasite.

Authors:  Adele M Lehane; Kevin J Saliba
Journal:  BMC Res Notes       Date:  2008-06-18
View more
  17 in total

1.  Variations in key artemisinic and other metabolites throughout plant development in Artemisia annua L. for potential therapeutic use.

Authors:  Melissa J Towler; Pamela J Weathers
Journal:  Ind Crops Prod       Date:  2015-05-01       Impact factor: 5.645

2.  Artemisia annua dried leaf tablets treated malaria resistant to ACT and i.v. artesunate: Case reports.

Authors:  Nsengiyumva Bati Daddy; Luc Malemo Kalisya; Pascal Gisenya Bagire; Robert L Watt; Melissa J Towler; Pamela J Weathers
Journal:  Phytomedicine       Date:  2017-04-14       Impact factor: 5.340

3.  Response to Argemi et al. 2019.

Authors:  Lucile Cornet-Vernet; Jerome Munyangi; Lu Chen; Melissa Towler; Pamela Weathers
Journal:  Phytomedicine       Date:  2019-05-09       Impact factor: 5.340

4.  It is not just artemisinin: Artemisia sp. for treating diseases including malaria and schistosomiasis.

Authors:  B M Gruessner; L Cornet-Vernet; M R Desrosiers; P Lutgen; M J Towler; P J Weathers
Journal:  Phytochem Rev       Date:  2019-09-19       Impact factor: 5.374

5.  YiXin-Shu, a ShengMai-San-based traditional Chinese medicine formula, attenuates myocardial ischemia/reperfusion injury by suppressing mitochondrial mediated apoptosis and upregulating liver-X-receptor α.

Authors:  Yichao Zhao; Longwei Xu; Zhiqing Qiao; Lingchen Gao; Song Ding; Xiaoying Ying; Yuanyuan Su; Nan Lin; Ben He; Jun Pu
Journal:  Sci Rep       Date:  2016-03-11       Impact factor: 4.379

6.  Cardioprotection by combination of three compounds from ShengMai preparations in mice with myocardial ischemia/reperfusion injury through AMPK activation-mediated mitochondrial fission.

Authors:  Fang Li; Xiaoxue Fan; Yu Zhang; Lizhi Pang; Xiaonan Ma; Meijia Song; Junping Kou; Boyang Yu
Journal:  Sci Rep       Date:  2016-11-21       Impact factor: 4.379

7.  Asteraceae Artemisia campestris and Artemisia herba-alba Essential Oils Trigger Apoptosis and Cell Cycle Arrest in Leishmania infantum Promastigotes.

Authors:  Zohra Aloui; Chokri Messaoud; Meriam Haoues; Noura Neffati; Imen Bassoumi Jamoussi; Khadija Essafi-Benkhadir; Mohamed Boussaid; Ikram Guizani; Habib Karoui
Journal:  Evid Based Complement Alternat Med       Date:  2016-10-11       Impact factor: 2.629

Review 8.  Artemisinin-based antimalarial research: application of biotechnology to the production of artemisinin, its mode of action, and the mechanism of resistance of Plasmodium parasites.

Authors:  Paskorn Muangphrom; Hikaru Seki; Ery Odette Fukushima; Toshiya Muranaka
Journal:  J Nat Med       Date:  2016-06-01       Impact factor: 2.343

Review 9.  A Systematic Review of Anti-malarial Properties, Immunosuppressive Properties, Anti-inflammatory Properties, and Anti-cancer Properties of Artemisia Annua.

Authors:  Samira Alesaeidi; Sepide Miraj
Journal:  Electron Physician       Date:  2016-10-25

Review 10.  Biotechnological approaches for artemisinin production in Artemisia.

Authors:  Waqas Khan Kayani; Bushra Hafeez Kiani; Erum Dilshad; Bushra Mirza
Journal:  World J Microbiol Biotechnol       Date:  2018-03-27       Impact factor: 3.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.